According to GlobalData’s medical device pipeline database, 309 Injectable Drug Delivery devices are in various stages of development globally. GlobalData’s report Injectable drug delivery provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Of these devices, 213 are in active development, while the remaining 102 are in an inactive stage of development. There are 113 products in the early stages of development, and the remaining 100 are in the late stages of development.
Drug delivery devices are used for administration of drug compounds in effective ways. Injectable drug delivery is a administers medication directly into the body through a needle or cannula. It is a fast and effective way to deliver drugs, and it can be used to treat a wide range of conditions, including pain, inflammation, and infection.
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Injectable Drug Delivery pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of Injectable Drug Delivery devices. Overall, most of these Injectable Drug Delivery pipeline devices are being developed by private entities.
Key players involved in the active development of Injectable Drug Delivery include IntraGel Therapeutics, Unilife, Windgap Medical, Ypsomed, Antares Pharma, EyePoint Pharmaceuticals, DALI Medical Devices, FluGen, Camurus and Milestone Scientific.
For a complete picture of the developmental pipeline for Injectable Drug Delivery devices, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. The Pipeline Products database is a is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.
